Lawson Health Research Institute Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4

Organization Overview

First Clinical Trial
2011
NCT01468155
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Allan Skanes | Jinka Sathya | Michael Kovacs | Pediatric Surgeon, Children's Hospital, LHSC | Ruby Grewal | Verinder Sharma

Active Ingredients

Drugs in Phase 4 Trials (3)

betamethasone (celestone) (1 trial)

dabigatran (pradaxa) (1 trial)

tranexamic acid (cyklokapron) (1 trial)

Drugs in Phase 3 Trials (1)

indocyanine green (ic-green) (1 trial)

Drugs in Phase 2 Trials (1)

hydrogen peroxide (1 trial)

Drugs in Phase 1 Trials (1)

quetiapine (seroquel) (1 trial)

Drugs in Other Trials (1)

apixaban (eliquis) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrial Fibrillation (Phase 4)

Trigger Finger Disorder (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 7
  • # of Trial APIs: 7